PNT 2003
Alternative Names: LU 177-SSTR- PNT-2003; LU-177 PNT 2003; Lutetium-177 Octreotate; PNT-2003Latest Information Update: 28 Dec 2024
Price :
$50 *
At a glance
- Originator POINT Biopharma
- Class Antineoplastics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Neuroendocrine tumours
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for clinical-Phase-Unknown development in Neuroendocrine-tumours(In adolescents, In the elderly, In adults) in Canada
- 27 Dec 2023 POINT Biopharma has been acquired by Eli Lilly and Company
- 27 Mar 2023 Lantheus and Point Biopharma closes its strategic collaboration and exclusive license agreements for PNT 2002 and PNT 2003